Repligen Corp
Biotechnology company · Waltham, Massachusetts, United States · Nasdaq: RGEN
Repligen Corp is a biotechnology company headquartered in Waltham, Massachusetts, United States. Its shares trade on Nasdaq under the ticker RGEN. It has received 7 US government small-business research awards (SBIR/STTR) from health agencies, $1.2 million in total, most recently in 2002. It has reported private securities offerings to the US SEC, most recently $48 million sold in a notice filed in 2019.
Repligen at a glance
What does Repligen do?
US government research funding
7 SBIR/STTR small-business research awards from US health agencies, $1.2 million in total (1991 to 2002).
Private fundraising reported to the SEC
2 Form D notices; the most recent reported $48 million sold (2019).
Frequently asked questions about Repligen
Where is Repligen headquartered?
Repligen Corp is headquartered in Waltham, Massachusetts, United States.
What does Repligen do?
Repligen Corp is a biotechnology company. Its SEC industry classification is Biological Products, (No Diagnostic Substances).
Is Repligen a public company?
Yes. Repligen Corp trades on Nasdaq under the ticker RGEN.
Similar companies
- TScan Therapeutics, Inc.Waltham, Massachusetts, United States
- Recursion PharmaceuticalsSalt Lake City, Utah, United States
- Vericel CorpBurlington, Massachusetts, United States
- SAB Biotherapeutics, Inc.Miami Beach, Florida, United States
- Adaptive Biotechnologies CorpSeattle, Washington, United States
- Inhibikase Therapeutics, Inc.Wilmington, Delaware, United States
- Cognition Therapeutics IncPurchase, New York, United States
- Agenus IncLexington, Massachusetts, United States
Need a CRO or CDMO for your next study?
Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.
Compare quotesSources
Location data: GeoNames (geonames.org), CC BY 4.0.
Last updated 2026-09-23.